Mytoxid Special Precautions

The drug should be used under constant supervision from physicians experienced in cancer chemotherapy, and it should be administered only to hospitalized patients who receive frequent determinations of hematopoietic, renal, and pulmonary function.
Patients receiving Mitomycin should be informed of the drug's potential toxicity, particularly bone marrow suppression; deaths have been reported due to septicemia as a result of leukopenia due to the drug.
Patients receiving Mitomycin should be observed for evidence of renal toxicity. Mitomycin should not be given to patients with a serum creatinine greater than 1.7 mg%.
Pharmaceutical Precautions: Cellulitis at the injection site has occurred and is occasionally severe.
Care should be taken to avoid extravasations of the drug.
When reconstituted solution is added to infusion fluids, especially when these contain dextrose, the resulting solution should be used immediately.
Use in Pregnancy & Lactation: Mitomycin has produced teratogenic effects in animals. Safe use of Mitomycin in pregnant women has not been established.
Safe use of mitomycin in lactation has not been established.
Use in Children: Should be cautioned for the appearance of adverse effects.